BACKGROUND: The purpose of this study was to determine if there are differences in biomarker modulation and epidermal growth factor receptor (EGFR) degradation between the tumor and the normal mucosa after treatment with an EGFR inhibitor, erlotinib, in head and neck cancer. METHODS: Patients with primary oral cavity squamous cell cancers received a course of erlotinib, 150 mg every day for 7 days before surgical resection. Tumor and normal mucosa biopsies were obtained both pre-erlotinib and post-erlotinib. Changes in known markers of EGFR activity (phospho, AKT, STAT3) were measured by immunoblotting, whereas changes in tissue distribution were analyzed by immunohistochemical analysis. RESULTS: Twelve patients were enrolled; 7 had evaluable paired tumors and normal mucosa biopsies pretreatment and posttreatment. Expression of EGFR was higher in tumors compared to the normal mucosa (p = .005). Erlotinib administration was associated with marked inhibition of phosphorylated epidermal growth factor receptor (pEGFR) and reduction in total EGFR protein (p = .004, p = .007) in tumors, whereas there was heterogeneity in EGFR inhibition in the normal mucosa (p = .10 [pEGFR], and p = .07 [EGFR]). Reduced levels of pSrc and pSTAT3 and enhanced p27 levels were noted in tumors after erlotinib. Cell culture studies confirmed that EGFR is degraded in tumor cells after prolonged treatment with erlotinib. CONCLUSION: Our results show that EGFR inhibition by erlotinib led to a marked reduction in EGFR protein levels in patients. Differential effects of erlotinib on tumors compared to the normal mucosa suggest there may be individual patient heterogeneity. These preliminary data suggest EGFR degradation should be further analyzed as a potential biomarker in selecting patients likely to benefit from EGFR inhibitors.
BACKGROUND: The purpose of this study was to determine if there are differences in biomarker modulation and epidermal growth factor receptor (EGFR) degradation between the tumor and the normal mucosa after treatment with an EGFR inhibitor, erlotinib, in head and neck cancer. METHODS:Patients with primary oral cavity squamous cell cancers received a course of erlotinib, 150 mg every day for 7 days before surgical resection. Tumor and normal mucosa biopsies were obtained both pre-erlotinib and post-erlotinib. Changes in known markers of EGFR activity (phospho, AKT, STAT3) were measured by immunoblotting, whereas changes in tissue distribution were analyzed by immunohistochemical analysis. RESULTS: Twelve patients were enrolled; 7 had evaluable paired tumors and normal mucosa biopsies pretreatment and posttreatment. Expression of EGFR was higher in tumors compared to the normal mucosa (p = .005). Erlotinib administration was associated with marked inhibition of phosphorylated epidermal growth factor receptor (pEGFR) and reduction in total EGFR protein (p = .004, p = .007) in tumors, whereas there was heterogeneity in EGFR inhibition in the normal mucosa (p = .10 [pEGFR], and p = .07 [EGFR]). Reduced levels of pSrc and pSTAT3 and enhanced p27 levels were noted in tumors after erlotinib. Cell culture studies confirmed that EGFR is degraded in tumor cells after prolonged treatment with erlotinib. CONCLUSION: Our results show that EGFR inhibition by erlotinib led to a marked reduction in EGFR protein levels in patients. Differential effects of erlotinib on tumors compared to the normal mucosa suggest there may be individual patient heterogeneity. These preliminary data suggest EGFR degradation should be further analyzed as a potential biomarker in selecting patients likely to benefit from EGFR inhibitors.
Authors: Christine H Chung; Kim Ely; Loris McGavran; Marileila Varella-Garcia; Joel Parker; Natalie Parker; Carolyn Jarrett; Jesse Carter; Barbara A Murphy; James Netterville; Brian B Burkey; Robert Sinard; Anthony Cmelak; Shawn Levy; Wendell G Yarbrough; Robbert J C Slebos; Fred R Hirsch Journal: J Clin Oncol Date: 2006-09-01 Impact factor: 44.544
Authors: Mukesh K Nyati; Felix Y Feng; Divya Maheshwari; Sooryanarayana Varambally; Steven P Zielske; Aarif Ahsan; Patrick Y Chun; Vinay A Arora; Mary A Davis; Mira Jung; Mats Ljungman; Christine E Canman; Arul M Chinnaiyan; Theodore S Lawrence Journal: Cancer Res Date: 2006-12-15 Impact factor: 12.701
Authors: F Y Feng; S Varambally; S A Tomlins; P Y Chun; C A Lopez; X Li; M A Davis; A M Chinnaiyan; T S Lawrence; M K Nyati Journal: Oncogene Date: 2006-12-04 Impact factor: 9.867
Authors: John C Sok; Francesca M Coppelli; Sufi M Thomas; Miriam N Lango; Sichuan Xi; Jennifer L Hunt; Maria L Freilino; Michael W Graner; Carol J Wikstrand; Darell D Bigner; William E Gooding; Frank B Furnari; Jennifer R Grandis Journal: Clin Cancer Res Date: 2006-09-01 Impact factor: 12.531
Authors: Felix Y Feng; Carlos A Lopez; Daniel P Normolle; Sooryanarayana Varambally; Xiaoxin Li; Patrick Y Chun; Mary A Davis; Theodore S Lawrence; Mukesh K Nyati Journal: Clin Cancer Res Date: 2007-04-15 Impact factor: 12.531
Authors: Bijan Khademi; Farzaneh Mohammadalizadeh Shirazi; Mohammad Vasei; Mehrnoosh Doroudchi; Behrouz Gandomi; Helmout Modjtahedi; Abdul Mohammad Pezeshki; Abbas Ghaderi Journal: Cancer Lett Date: 2002-10-28 Impact factor: 8.679
Authors: Y Lemos-González; M Páez de la Cadena; F J Rodríguez-Berrocal; A M Rodríguez-Piñeiro; E Pallas; D Valverde Journal: Tumour Biol Date: 2007-10-26
Authors: Mark Agulnik; Gilda da Cunha Santos; David Hedley; Trudey Nicklee; Patricia Pintor Dos Reis; James Ho; Gregory R Pond; Heidi Chen; Shuo Chen; Yu Shyr; Eric Winquist; Denis Soulieres; Eric X Chen; Jeremy A Squire; Paula Marrano; Suzanne Kamel-Reid; Janet Dancey; Lillian L Siu; Ming S Tsao Journal: J Clin Oncol Date: 2007-06-01 Impact factor: 44.544
Authors: Fabienne Thomas; Philippe Rochaix; Adil Benlyazid; Jérôme Sarini; Michel Rives; Jean Louis Lefebvre; Ben C Allal; Frédéric Courbon; Etienne Chatelut; Jean-Pierre Delord Journal: Clin Cancer Res Date: 2007-12-01 Impact factor: 12.531
Authors: Julie E Bauman; Umamaheswar Duvvuri; William E Gooding; Tanya J Rath; Neil D Gross; John Song; Antonio Jimeno; Wendell G Yarbrough; Faye M Johnson; Lin Wang; Simion Chiosea; Malabika Sen; Jason Kass; Jonas T Johnson; Robert L Ferris; Seungwon Kim; Fred R Hirsch; Kimberly Ellison; John T Flaherty; Gordon B Mills; Jennifer R Grandis Journal: JCI Insight Date: 2017-03-23
Authors: Daniel L Gillen; Frank L Meyskens; Timothy R Morgan; Jason A Zell; Robert Carroll; Richard Benya; Wen-Pin Chen; Allen Mo; Chris Tucker; Asmita Bhattacharya; Zhiliang Huang; Myra Arcilla; Vanessa Wong; Jinah Chung; Rachel Gonzalez; Luz Maria Rodriguez; Eva Szabo; Daniel W Rosenberg; Steven M Lipkin Journal: Cancer Prev Res (Phila) Date: 2015-01-20
Authors: Paula M Fracasso; Linda R Duska; Premal H Thaker; Feng Gao; Imran Zoberi; Farrokh Dehdashti; Barry A Siegel; Livnat Uliel; Christine O Menias; Patrice K Rehm; Sherry A Goodner; Allison N Creekmore; Heather L Lothamer; Janet S Rader Journal: Am J Clin Oncol Date: 2022-06-07 Impact factor: 2.787
Authors: Cara B Gonzales; Jorge J De La Chapa; Pothana Saikumar; Prajjal K Singha; Nicholas F Dybdal-Hargreaves; Jeffery Chavez; Aaron M Horning; Jamie Parra; Nameer B Kirma Journal: Oral Oncol Date: 2016-08 Impact factor: 5.337
Authors: Thomas J Knobloch; Lana K Uhrig; Dennis K Pearl; Bruce C Casto; Blake M Warner; Steven K Clinton; Christine L Sardo-Molmenti; Jeanette M Ferguson; Brett T Daly; Kenneth Riedl; Steven J Schwartz; Yael Vodovotz; Anthony J Buchta; David E Schuller; Enver Ozer; Amit Agrawal; Christopher M Weghorst Journal: Cancer Prev Res (Phila) Date: 2015-12-23